Reference Detail

Ref Type Journal Article
PMID (23493885)
Authors D'Arcangelo M, Cappuzzo F
Title Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer.
Journal Biologics : targets & therapy
Vol 7
Issue
Date 2013
URL
Abstract Text Lung cancer treatment has rapidly changed in the last few years thanks to novel insights into cancer biology. Several biomarkers and signaling pathways have been recognized as conceivable targets for treatment, and among them is the mesenchymal-epithelial transition/hepatocyte growth factor (c-MET/HGF) axis. Alterations in the c-MET gene and aberrations of MET and HGF expression impact on lung cancer prognosis and are involved in resistance to epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations. Several anti-MET and anti-HGF strategies are currently under investigation, including monoclonal antibodies. Ficlatuzumab is a monoclonal antibody directed against HGF that is currently under investigation in NSCLC. The aim of the present review is to critically review available data on HGF and ficlatuzumab in NSCLC.

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Therapy Description
Ficlatuzumab Ficlatuzumab is a monoclonal antibody that targets HGF and inhibits c-MET/HGF signaling, potentially resulting in decreased tumor growth (PMID: 23493885).
Drug Name Trade Name Synonyms Drug Classes Drug Description
Ficlatuzumab AV-299|SCH900105 HGF Antibody 4 Ficlatuzumab is a monoclonal antibody that targets HGF and inhibits c-MET/HGF signaling, potentially resulting in decreased tumor growth (PMID: 23493885).
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown non-small cell lung carcinoma not applicable Ficlatuzumab + Gefitinib Phase I Actionable In a Phase I trial, Ficlatuzumab (Av-299) in combination with Iressa (gefitinib) demonstrated safety and efficacy in patients with NSCLC (PMID: 23493885, J Clin Oncol. 2011;29(Suppl 15) Abstract 7571). detail... 23493885
Unknown unknown Advanced Solid Tumor not applicable Ficlatuzumab + Erlotinib Phase I Actionable In a Phase I trial, Ficlatuzumab (AV-299) in combination with Tarceva (erlotinib) was shown to be safe in treating patients with advanced solid tumors (PMID: 23493885, J Clin Oncol. 2010;28(Suppl) Abstract 2525). 23493885 detail...